Clinical Outcome of Patients With Upper-Extremity Deep Vein Thrombosis

Duplex sonography for detection of deep vein thrombosis of upper extremities: a 13-year experience

“…In our study, malignancy was a major risk factor for UEDVT, similar to studies conducted in Caucasian population. 1,3,4 In our study, the frequency of cancer (65.5%) was even higher than those in Caucasian population in other studies, which had 43%, 15 30%, 16 38%, 17 and 45%. 4 Similar studies on Chinese population have already been published.…”

Deep Vein Thrombosis of the Arms

“…Recently, the prospective RIETE registry and the population based Malmö thrombophilia study reported both very similar rates of upper extremity deep vein thrombosis (4.4% and 5% of all thrombosis, respectively (Munoz et al, 2008;Isma et al, 2010). Therefore, it can be assumed that about 5% of all thrombosis will involve the deep arm veins, which corresponds to an annual incidence of approximately 3 per 100.000 patients per year (Bernardi et al, 2006).…”

“…However, even patients that are treated according to current guidelines have a significant risk of severe complications (Table 3). Compared to lower extremity deep vein thrombosis, patients with deep arm vein thrombosis present less frequently with concomitant pulmonary embolism (9% versus 30%) (Munoz et al, 2008;Lechner et al, 2008). However, pulmonary embolism caused by deep arm vein thrombosis can even be fatal in rare cases (Monreal et al, 1994).…”

“…Although this holds true for over 90% of all thromboses, clinically relevant thromboses may be found in virtually every vein system of the body. Of these uncommon localisations of thromboses, deep vein thrombosis of the arms is one of the most frequent entities, accounting for about 5% of all thromboses (Munoz et al, 2008;Isma et al, 2010). Most cases of deep arm vein thrombosis develop secondary in patients with indwelling central venous catheters, pacemakers, malignant disease, or after surgery.…”

Treatment of central venous catheter‐associated deep venous thrombosis in cancer patients with rivaroxaban

“…Major bleeding events occurred in two patients treated with rivaroxaban, with an estimate of 2.4%. In The Catheter Study and the upper‐Extremity DVT arm of the RIETE trial, major bleeding was reported in 10.9% and 2.1%, respectively 3, 6.…”